Mitochondrial complex II and reactive oxygen species in disease and therapy
File version
Version of Record (VoR)
Author(s)
Kraus, Michal
Neuzil, Jiri
Rohlena, Jakub
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
Increasing evidence points to the respiratory Complex II (CII) as a source and modulator of reactive oxygen species (ROS). Both functional loss of CII as well as its pharmacological inhibition can lead to ROS generation in cells, with a relevant impact on the development of pathophysiological conditions, i.e. cancer and neurodegenerative diseases. While the basic framework of CII involvement in ROS production has been defined, the fine details still await clarification. It is important to resolve these aspects to fully understand the role of CII in pathology and to explore its therapeutic potential in cancer and other diseases.
Journal Title
Redox Report
Conference Title
Book Title
Edition
Volume
25
Issue
1
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Item Access Status
Note
Access the data
Related item(s)
Subject
Pharmacology and pharmaceutical sciences
Science & Technology
Life Sciences & Biomedicine
Biochemistry & Molecular Biology
Respiratory complex II
succinate dehydrogenase
Persistent link to this record
Citation
Vanova, KH; Kraus, M; Neuzil, J; Rohlena, J, Mitochondrial complex II and reactive oxygen species in disease and therapy, Redox Report, 2020, 25 (1), pp. 26-32